Jefferies Group LLC restated their buy rating on shares of Kite Pharma, Inc. (NASDAQ:KITE) in a research report report published on Wednesday morning. The firm currently has a $135.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $121.00. Jefferies Group also issued estimates for Kite Pharma’s Q3 2017 earnings at ($2.26) EPS, Q4 2017 earnings at ($2.49) EPS, FY2017 earnings at ($8.36) EPS, FY2018 earnings at ($6.61) EPS, FY2019 earnings at ($0.91) EPS, FY2020 earnings at $4.79 EPS and FY2021 earnings at $7.32 EPS.

Other equities analysts also recently issued reports about the company. Maxim Group set a $88.00 price objective on Kite Pharma and gave the company a buy rating in a research report on Tuesday, May 9th. Goldman Sachs Group, Inc. (The) boosted their price objective on Kite Pharma from $85.00 to $89.00 and gave the company a buy rating in a research report on Tuesday, May 9th. Canaccord Genuity restated a buy rating and issued a $90.00 price objective on shares of Kite Pharma in a research report on Tuesday, May 9th. Vetr upgraded Kite Pharma from a hold rating to a buy rating and set a $85.40 price objective on the stock in a research report on Monday, May 8th. Finally, HC Wainwright restated a buy rating and issued a $85.00 price objective on shares of Kite Pharma in a research report on Friday, May 19th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of $88.93.

Shares of Kite Pharma (KITE) traded down 0.46% during trading on Wednesday, reaching $120.04. The company’s stock had a trading volume of 872,923 shares. The company’s market cap is $6.86 billion. Kite Pharma has a 12-month low of $39.82 and a 12-month high of $122.19. The company has a 50 day moving average of $107.82 and a 200 day moving average of $81.83.

Kite Pharma (NASDAQ:KITE) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.97) by $0.03. Kite Pharma had a negative return on equity of 59.56% and a negative net margin of 1,117.44%. The business had revenue of $10.10 million for the quarter, compared to the consensus estimate of $9.59 million. During the same period in the previous year, the business earned ($0.91) earnings per share. The business’s revenue was up 110.4% on a year-over-year basis. On average, analysts anticipate that Kite Pharma will post ($8.35) EPS for the current fiscal year.

WARNING: “Kite Pharma’s (NASDAQ:KITE) Buy Rating Reiterated at Jefferies Group LLC” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://theolympiareport.com/2017/08/12/kite-pharmas-nasdaqkite-buy-rating-reiterated-at-jefferies-group-llc.html.

In other Kite Pharma news, COO Cynthia M. Butitta sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $100.81, for a total transaction of $504,050.00. Following the sale, the chief operating officer now directly owns 114,845 shares of the company’s stock, valued at $11,577,524.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Cynthia M. Butitta sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $88.55, for a total value of $885,500.00. Following the sale, the chief operating officer now directly owns 127,795 shares in the company, valued at $11,316,247.25. The disclosure for this sale can be found here. Insiders have sold 245,048 shares of company stock worth $25,803,151 over the last three months. 14.00% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of KITE. Vanguard Group Inc. boosted its stake in shares of Kite Pharma by 9.2% in the second quarter. Vanguard Group Inc. now owns 3,998,269 shares of the biopharmaceutical company’s stock valued at $414,501,000 after buying an additional 336,722 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Kite Pharma by 10.3% in the second quarter. BlackRock Inc. now owns 3,995,272 shares of the biopharmaceutical company’s stock valued at $414,190,000 after buying an additional 373,301 shares during the last quarter. Menora Mivtachim Holdings LTD. boosted its stake in shares of Kite Pharma by 13.9% in the first quarter. Menora Mivtachim Holdings LTD. now owns 1,433,899 shares of the biopharmaceutical company’s stock valued at $112,547,000 after buying an additional 175,000 shares during the last quarter. Point72 Asset Management L.P. boosted its stake in shares of Kite Pharma by 235.0% in the first quarter. Point72 Asset Management L.P. now owns 819,900 shares of the biopharmaceutical company’s stock valued at $64,354,000 after buying an additional 575,178 shares during the last quarter. Finally, First Trust Advisors LP boosted its stake in shares of Kite Pharma by 0.5% in the first quarter. First Trust Advisors LP now owns 610,572 shares of the biopharmaceutical company’s stock valued at $47,924,000 after buying an additional 3,300 shares during the last quarter. 84.96% of the stock is currently owned by institutional investors.

About Kite Pharma

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.

Analyst Recommendations for Kite Pharma (NASDAQ:KITE)

Receive News & Ratings for Kite Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.